Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
Navinet and Vitality use Internet for Health, Constellation Gets to Series A, and Other Boston-Area Life Sciences News
|
Eric Hal Schwartz |
08/19/09 |
Boston
|
|
Next 10 to Sign Up for XSITE 2009 are Eligible to Win a Garmin GPS System—So Hurry Up and Navigate to the Registration Site
|
Editors |
06/09/09 |
Boston
|
|
The Health 2.0 Hub, Boston’s Secret Entertainment Cluster, A Path to Market for Energy Innovations, Dean Kamen, and more XSITEment
|
Robert Buderi |
06/02/09 |
Boston
|
|
Isis, Alnylam to Collaborate on Single-Stranded RNA Drugs; Deal Could Add Up to $31 Million to Isis’ Coffers
|
Wade Roush |
04/29/09 |
San Diego
|
|
Regulus Strikes Out On Its Own, J&J Seeks “Enlight”-enment, Synta Awaits Melanoma Data, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
01/28/09 |
Boston
|
|
Alnylam, Cubist Will Cooperate on RNAi Drug for Lung Infections
|
Wade Roush |
01/09/09 |
Boston
|
|
New RNAi Drugs, Major Cutbacks at Targanta, Big Partnerships for Arqule and Archemix, & More Boston-Area Life Sciences News
|
Wade Roush |
12/24/08 |
Boston
|
|
No Appeal for Boston Scientific, No Luck for CombinatoRx Drug, No Complaints From Harvard, & More Boston-Area Life Sciences News
|
Rebecca Zacks |
10/08/08 |
Boston
|
|
Alnylam Hires Chief Scientist, Jack Schmidt, To Help Build RNAi Pipeline
|
Luke Timmerman |
10/01/08 |
Boston
|
|
Alnylam, RXi On Collision Course Over Intellectual Property From Massachusetts Life Sciences Initiative
|
Luke Timmerman |
09/19/08 |
Boston
|
|
Alnylam Sees Opportunity in Turning Genes On, And Off
|
Luke Timmerman |
09/05/08 |
Boston
|
|
Alnylam’s In the Money: Expects $500 Million in Bank at Year-End
|
Luke Timmerman |
08/06/08 |
Boston
|
|
Alnylam’s Ebola Work Gets $7.5 Million Commitment
|
Luke Timmerman |
08/06/08 |
Boston
|
|
Alnylam Obtains Intellectual Property For RNA Activation, Turning Genes On Instead of Off
|
Luke Timmerman |
08/04/08 |
Boston
|
|
Alnylam, Novartis Extend RNA Interference Collaboration
|
Luke Timmerman |
07/16/08 |
Boston
|
|
Alnylam Loses RNAi Patent in Europe; Analyst Says No Worries
|
Luke Timmerman |
07/11/08 |
Boston
|
|
Alnylam Inks $93M Japanese Deal
|
Rebecca Zacks |
06/19/08 |
Boston
|
|
$400M Contract for Foster-Miller, 65K Order for OLPC, $1B In, $5M Out for Alnylam, & More Deals News
|
Rebecca Zacks |
06/03/08 |
Boston
|
|
Alnylam Inks $1 Billion Deal with Takeda
|
Gregory T. Huang |
05/27/08 |
Boston
|
|
BSX Meets With Much Approval, Biogen and Icahn Set the (Showdown) Date, Fate’s Fate Revealed, Win Free Stuff, & More Life Sciences News
|
Rebecca Zacks |
05/14/08 |
Boston
|
|
Novartis Increases Stake in Alnylam
|
Wade Roush |
05/08/08 |
Boston
|
|
Three Luminaries, Two Third Revolutions, and One Nice Suit: An Xconomy Forum on the Future of Life Sciences in New England
|
Rebecca Zacks |
05/02/08 |
Boston
|
|
Heavyweight Hydrogen Takes $37 Million Prize for Concert Pharmaceuticals
|
Erik Mellgren |
05/01/08 |
Boston
|
|
GSK Takes Sirtris and Taps Alnylam Venture, FDA Deals Genzyme Drug a Blow, Resolvyx Finances Fish-Oil Drugs, & More Life Sciences News
|
Rebecca Zacks |
04/23/08 |
Boston
|
|
Alnylam Joint Venture Regulus Inks Deal with GSK Worth up to $600 Million
|
Erik Mellgren |
04/17/08 |
Boston
|
|
In Latest Local Venture Philanthropy Deal, Cystic Fibrosis Foundation Pledges up to $37.7 More to Epix
|
Rebecca Zacks |
04/07/08 |
Boston
|
|
Mello RNAi Firm RXi Pharmaceuticals Has Wild Ride on First Day of Trading
|
Rebecca Zacks |
03/12/08 |
Boston
|
|
Thermo Fisher Simplifies RNAi Delivery
|
Wade Roush |
03/10/08 |
Boston
|
|
Biogen’s Busy Week, Alnylam’s Big Announcement, Targanta’s and Momenta’s Growing Executive Ranks, & More Life Sciences News
|
Rebecca Zacks |
03/05/08 |
Boston
|
|
Alnylam Touts Early Evidence of RNAi Drug Efficacy
|
Wade Roush |
02/29/08 |
Boston
|
|
Page 1 of
2 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
